Sanara MedTech (SMTI) to Release Quarterly Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) is projected to post its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Sanara MedTech to post earnings of $0.11 per share and revenue of $27.20 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 8:00 AM ET.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.19) earnings per share (EPS) for the quarter. The business had revenue of $27.55 million during the quarter. Sanara MedTech had a negative return on equity of 21.33% and a negative net margin of 36.79%. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Stock Performance

Shares of SMTI opened at $18.08 on Wednesday. The company has a debt-to-equity ratio of 7.34, a current ratio of 1.80 and a quick ratio of 1.60. The firm’s 50 day moving average is $20.36 and its 200-day moving average is $24.67. Sanara MedTech has a 12-month low of $17.54 and a 12-month high of $35.95. The stock has a market capitalization of $160.91 million, a P/E ratio of -4.28 and a beta of 1.04.

Hedge Funds Weigh In On Sanara MedTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its stake in shares of Sanara MedTech by 127.3% in the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock valued at $2,747,000 after acquiring an additional 65,887 shares in the last quarter. Marshall Wace LLP boosted its holdings in Sanara MedTech by 144.3% in the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after purchasing an additional 42,237 shares during the period. Squarepoint Ops LLC grew its position in Sanara MedTech by 343.4% in the 3rd quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock worth $996,000 after purchasing an additional 24,305 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Sanara MedTech during the 4th quarter worth about $355,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Sanara MedTech during the second quarter valued at about $382,000. Institutional investors own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. Zacks Research lowered Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Sanara MedTech in a research note on Monday, January 26th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $41.00.

Key Stories Impacting Sanara MedTech

Here are the key news stories impacting Sanara MedTech this week:

• Positive Sentiment: Company reaffirmed full‑year 2026 financial guidance and reported revenue growth: Q4 net revenue rose ~5% to $27.5M, and management left 2026 guidance intact — supportive for forward expectations. GlobeNewswire Release
• Positive Sentiment: Early market reaction: some outlets reported an intraday pop (shares rose >3%) despite the reported earnings miss, suggesting some investors focused on revenue/guidance or other qualitative takeaways from the release/call. MSN Article Investing.com Article
• Neutral Sentiment: Earnings call transcript and conference-call materials are available for deeper read — useful for investors who want management color on growth drivers, margins and 2026 execution. Seeking Alpha Transcript Press Release / Call Materials
• Neutral Sentiment: Short‐interest notices in multiple feeds showed a “large increase” but reported zero shorted shares and a 0.0 days‑to‑cover metric — this appears to be a reporting/data anomaly rather than actionable short selling pressure. (Multiple internal short‑interest entries.)
• Negative Sentiment: Q4 earnings metrics disappointed: outlets report an earnings miss versus consensus (Zacks: $0.04 vs est. $0.11) and some sources recorded a negative EPS figure and weak margins/ROE — a direct negative to near‑term sentiment. Zacks Earnings Coverage MarketBeat Summary

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.